Truemeds key facts
as of Oct 2026- Operator of a telehealth platform intended to make healthcare accessible to every patient.
- Truemeds is valued at approximately $331.0M as of Oct 2026 (last reported valuation).
- It has raised $113.2M; the latest was Later Stage VC ($64.0M) in Jul 2025.
- Notable investors include Accel, Peak XV Partners, Prosus Ventures, Indian Angel Network, InfoEdge Ventures — 14 tracked in total.
- Status: Privately Held (backing).
Truemeds's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Truemeds: the Monday email on marks, rounds and moves
Truemeds funding rounds
No funding rounds for Truemeds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Truemeds
14+Truemeds valuation
Truemeds's last reported valuation was $331 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Truemeds investors
14 investors are on record for Truemeds, including Accel, Peak XV Partners, Prosus Ventures and Indian Angel Network. By type, the record holds 4 venture capital firms, 1 angel investor and 1 growth equity firm.
About Truemeds
Operator of a telehealth platform intended to make healthcare accessible to every patient. The company's platform advises patients about substitute medicines offered by reputed pharmaceutical companies and recommends appropriate value medicines to customers with precise scientific matching and outcome history, enabling patients to choose the right medicine at an affordable price.
- Sector
- Healthcare
- HQ
- Mumbai, India
- Founded
- 2018
- Employees
- 3,000
- Website
- truemeds.in/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.